DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Keryx Biopharmaceuticals, Inc. Of Upcoming Deadline
September 16 2016 - 12:20PM
Business Wire
Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of
Keryx Biopharmaceuticals, Inc. (NASDAQ CM:
KERX)?
- Did you purchase your shares between
February 25, 2016 and August 1, 2016, inclusive?
- Did you lose money in your
investment?
Rigrodsky & Long, P.A. reminds shareholders of Keryx
Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (NASDAQ CM:
KERX) of an upcoming deadline involving a securities fraud class
action lawsuit commenced against the Company. A complaint was filed
in the United States District Court for the Southern District of
New York on behalf of all persons or entities that purchased the
common stock of Keryx between February 25, 2016 and August 1, 2016,
inclusive (the “Class Period”), alleging violations of the
Securities Exchange Act of 1934 against the Company and certain of
its officers (the “Complaint”).
The Complaint alleges that throughout the Class Period,
defendants made materially false and misleading statements, and
omitted materially adverse facts, about the Company’s business,
operations and prospects. Specifically, the Complaint alleges that
the defendants concealed from the investing public that: (1) that
the Company was experiencing production-related difficulties in
converting active pharmaceutical ingredient (“API”) to finished
drug product; (2) that the issue was resulting in decreased
production yields of finished drug product; (3) that, as a result,
the Company would, and did exhaust its reserve of finished drug
product; and (4) that, as a result of the foregoing, Defendants’
statements about Keryx’s business, operations, and prospects, were
false and misleading and/or lacked a reasonable basis. As a result
of defendants’ alleged false and misleading statements, the
Company’s stock traded at artificially inflated prices during the
Class Period.
If you wish to serve as lead plaintiff, you must move the Court
no later than October 3, 2016. A lead plaintiff is a
representative party acting on behalf of other class members in
directing the litigation. Any member of the proposed class may move
the court to serve as lead plaintiff through counsel of their
choice, or may choose to do nothing and remain an absent class
member.
If you purchased shares of Keryx during the Class Period, or
purchased shares prior to the Class Period and still hold Keryx, and wish to discuss this
action or have any questions concerning this notice or your rights
or interests, please contact Timothy J. MacFall, Esquire or Peter
Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite
120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to
info@rl-legal.com; or at:
http://rigrodskylong.com/investigations/keryx-biopharmaceuticals-inc-kerx.
Attorney advertising. Prior results do not guarantee a similar
outcome.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160916005655/en/
Rigrodsky & Long, P.A.Timothy J. MacFall, EsquirePeter
Allocco888-969-4242516-683-3516Fax:
302-654-7530info@rl-legal.comhttp://www.rigrodskylong.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024